{"type":"trials","record":{"id":39257,"source_id":"clinicaltrials-gov","external_id":"NCT03389698","title":"Developing Advanced Blood-Brain Barrier Permeability Imaging for Early AD","brief_summary":"Aging is the primary risk factor in aging-related dementia. An important initiating factor for the development and progression of cognitive impairment is disruption of the blood-brain barrier (BBB). BBB plays an important role in maintaining normal brain homeostasis and protecting neural tissues from toxins. It is hypothesized that such changes known to be common in aging and can be an early process that precedes Alzheimer's Disease (AD). The microvascular changes related to subtle BBB disruption can be measured with permeability-surface area (PS) derived from GRASP DCE-MRI acquired less than 10 minutes, and the patterns of increased PS in normal and abnormal aging are different.","overall_status":"Completed","phases":[],"study_type":"OBSERVATIONAL","sponsor":"NYU Langone Health","enrollment":27,"countries":["United States"],"start_date":"2018-12-18","completion_date":"2023-07-11","last_update_date":"2024-01-30","source_url":"https://clinicaltrials.gov/study/NCT03389698","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:15.604755+00:00","last_seen_at":"2026-09-25T06:20:09.878+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"20 Years to 85 Years","comparator":null,"organization":"NYU Langone Health","interventions":["GRASP Dynamic Contrast-Enhanced (DCE) MRI","3T Brain Scan","Gadolinium-based Contrast Agent (GBCA) for MRI"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Permeability Surface Area (PS) as Measured by GRASP DCE-MRI Sequence — Up to 21 Minutes","Blood-Brain Barrier (BBB) Permeability as Measured by GRASP DCE-MRI Sequence — Up to 21 Minutes"],"design_description":null,"source_has_results":false},"controlled_terms":["Alzheimer Disease","GRASP Dynamic Contrast-Enhanced (DCE) MRI","3T Brain Scan","Gadolinium-based Contrast Agent (GBCA) for MRI"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: blood-brain barrier.","quality_checked_at":"2026-09-25T06:20:11.344357+00:00","duplicate_cluster_key":"id:nct03389698","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2018-12-18 to 2023-07-11","comparator":null,"confidence":"structured-source","population":"ALL · 20 Years to 85 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:09.903Z","intervention":["GRASP Dynamic Contrast-Enhanced (DCE) MRI","3T Brain Scan","Gadolinium-based Contrast Agent (GBCA) for MRI"],"participants":27,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Permeability Surface Area (PS) as Measured by GRASP DCE-MRI Sequence — Up to 21 Minutes","Blood-Brain Barrier (BBB) Permeability as Measured by GRASP DCE-MRI Sequence — Up to 21 Minutes"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"blood-brain-barrier-aging","is_published":true,"match_reasons":["Title contains controlled term: blood-brain barrier.","Abstract contains controlled term: blood-brain barrier.","Title supplies longevity context: aging.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["title","abstract","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Blood-brain barrier ageing","slug":"blood-brain-barrier-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/39257","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}